Josh Schimmer
Stock Analyst at Evercore ISI Group
(4.31)
# 361
Out of 5,241 analysts
150
Total ratings
53.73%
Success rate
15.77%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Outperform | $324 → $329 | $237.64 | +38.44% | 5 | May 15, 2026 | |
| ARTV Artiva Biotherapeutics | Maintains: Overweight | $10 → $40 | $9.22 | +333.84% | 3 | May 11, 2026 | |
| CABA Cabaletta Bio | Reiterates: Overweight | $30 | $3.29 | +811.85% | 4 | May 4, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $8 → $10 | $3.07 | +225.73% | 8 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $135 → $140 | $99.90 | +40.14% | 2 | Feb 27, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $150 → $100 | $14.03 | +612.76% | 8 | Feb 27, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $130 | $95.49 | +36.14% | 7 | Dec 8, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $5.65 | +342.48% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $105.05 | +90.39% | 1 | Nov 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $65.32 | +68.40% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $1.13 | +784.96% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $65 | $12.95 | +401.93% | 6 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $62.93 | +19.18% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.40 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $26.30 | -4.94% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $13.43 | +86.15% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $10.56 | -43.18% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $4.36 | +1,046.79% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $291.75 | -26.31% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.58 | +93.80% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.12 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $7.30 | +310.96% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.37 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.12 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $34.70 | +159.37% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.8065 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $107.15 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $73.95 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.03 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.96 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $14.09 | +751.67% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $53.71 | +21.02% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $10.27 | +7.11% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $157.21 | -17.31% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $629.68 | +20.70% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $24.43 | -38.60% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $14.87 | +269.87% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.40 | +2,050.54% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.44 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $5.65 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $522.23 | -52.13% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $95.19 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $72.52 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.53 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $24.93 | -11.75% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $16.26 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $49.67 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $209.41 | -54.63% | 1 | Aug 17, 2017 |
Ascendis Pharma
May 15, 2026
Maintains: Outperform
Price Target: $324 → $329
Current: $237.64
Upside: +38.44%
Artiva Biotherapeutics
May 11, 2026
Maintains: Overweight
Price Target: $10 → $40
Current: $9.22
Upside: +333.84%
Cabaletta Bio
May 4, 2026
Reiterates: Overweight
Price Target: $30
Current: $3.29
Upside: +811.85%
Rocket Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $3.07
Upside: +225.73%
Nuvalent
Feb 27, 2026
Maintains: Overweight
Price Target: $135 → $140
Current: $99.90
Upside: +40.14%
Janux Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $150 → $100
Current: $14.03
Upside: +612.76%
Mirum Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $95 → $130
Current: $95.49
Upside: +36.14%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $5.65
Upside: +342.48%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $105.05
Upside: +90.39%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $65.32
Upside: +68.40%
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $1.13
Upside: +784.96%
Sep 22, 2025
Maintains: Outperform
Price Target: $70 → $65
Current: $12.95
Upside: +401.93%
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $62.93
Upside: +19.18%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.40
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $26.30
Upside: -4.94%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $13.43
Upside: +86.15%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $10.56
Upside: -43.18%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $4.36
Upside: +1,046.79%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $291.75
Upside: -26.31%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.58
Upside: +93.80%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.12
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $7.30
Upside: +310.96%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.37
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.12
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $34.70
Upside: +159.37%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.8065
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $107.15
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $73.95
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.03
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.96
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $120
Current: $14.09
Upside: +751.67%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $53.71
Upside: +21.02%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $10.27
Upside: +7.11%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $157.21
Upside: -17.31%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $629.68
Upside: +20.70%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $24.43
Upside: -38.60%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $14.87
Upside: +269.87%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.40
Upside: +2,050.54%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.44
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $5.65
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $522.23
Upside: -52.13%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $95.19
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $72.52
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.53
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $24.93
Upside: -11.75%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $16.26
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $49.67
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $209.41
Upside: -54.63%